Urotensins

Teleost hormones. A family of small peptides isolated from urophyses of bony fishes. They have many different physiological effects, including long-lasting hypotensive activity and have been proposed as antihypertensives. There are at least four different compounds: urotensin I, urotensin II, urotensin III, and urotensin IV.

Also Known As:

Networked: 55 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ashton, Nick: 3 articles (01/2019 - 06/2012)
2.	Halici, Zekai: 3 articles (01/2019 - 09/2014)
3.	Behm, David J: 3 articles (01/2013 - 08/2008)
4.	Roy, Sudipto: 2 articles (01/2020 - 12/2018)
5.	Chen, Shuo: 2 articles (12/2019 - 01/2016)
6.	Chen, Zhi-Wu: 2 articles (12/2019 - 01/2016)
7.	Schwertani, Adel: 2 articles (09/2019 - 09/2016)
8.	Taysi, Seyithan: 2 articles (07/2019 - 04/2013)
9.	Akpinar, Erol: 2 articles (01/2019 - 09/2014)
10.	Cadirci, Elif: 2 articles (01/2019 - 01/2016)

Related Diseases

1.	Hypertension (High Blood Pressure) 08/15/2008 - "Select compounds were found to inhibit urotensin-induced vasoconstriction in isolated rat aortic rings consistent with the hypothesis that an urotensin antagonist may be useful for the treatment of hypertension." 01/01/2013 - "Since the urotensin system acts to regulate glomerular filtration in the kidney it may play a greater role in the pre-hypertensive SHR in which renal dysfunction is known to precede the onset of severe hypertension. " 02/01/2014 - "There are 2 candidate genes, AGTR1 (an angiotensin II type 1 receptor) and UTS2D (urotensin 2 domain containing), in this region that have been associated with hypertension and hypoxic response in mammals. " 08/01/2006 - "Moreover, an interaction between U-II and other endogenous vasoactive molecules may add a level of complexity to the vascular actions of U-II.On the other hand, recent experimental and clinical studies have revealed increased expression of U-II and urotensin receptor (UT receptor) in animals with experimentally induced myocardial infarction, heart failure, and in patients with hypertension, atherosclerosis, and diabetic nephropathy, which suggests a potential role for U-II in both cardiovascular and renal diseases. " 01/01/2020 - "Urotensin 2 (U-II), which is one of the most effective known vasoconstrictor peptides, was observed to act as a vasoconstrictor in diseases such as hypertension and heart failure, and to induce vasodilation in healthy volunteers. "
2.	Myocardial Infarction 03/01/2015 - "Postmortem urotensin receptor expression level for diagnosis of myocardial infarction-related deaths." 09/01/2014 - "Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?" 08/01/2010 - "Urotensin II (UII) is a potential mediator in the pathogenesis of cardiovascular disease, and inhibition of its actions at the urotensin receptor (UT) has been shown to improve cardiac function and structural changes of the myocardium in a model of myocardial infarction. " 08/01/2006 - "Moreover, an interaction between U-II and other endogenous vasoactive molecules may add a level of complexity to the vascular actions of U-II.On the other hand, recent experimental and clinical studies have revealed increased expression of U-II and urotensin receptor (UT receptor) in animals with experimentally induced myocardial infarction, heart failure, and in patients with hypertension, atherosclerosis, and diabetic nephropathy, which suggests a potential role for U-II in both cardiovascular and renal diseases. "
3.	Hypertrophy 08/01/2017 - "The model of urotensin II (UII)-induced cardiomyocyte hypertrophy has been widely used in studies on hypertrophy. " 01/01/2018 - "Moreover, H9c2 cells exposed to high glucose showed a significant reduction in cell viability (-40%), a significant increase in total protein per cell number (+109%), and an increase of the urotensin receptor expression levels as an evidence of cells hypertrophy. " 09/01/2004 - "The activation of ERK1/2 and p38 as well as cellular hypertrophy was independent of protein kinase C, and calcium and phosphoinositide 3-kinase, yet dependent on the capacity of the urotensin receptor to trans-activate the epidermal growth factor receptor. "
4.	Cardiovascular Diseases (Cardiovascular Disease) 05/01/2015 - "Blockade of the actions of urotensin-II (U-II) mediated by the urotensin (UT) receptor should improve cardiac function and prevent cardiac remodelling in cardiovascular disease. " 08/01/2010 - "Urotensin II (UII) is a potential mediator in the pathogenesis of cardiovascular disease, and inhibition of its actions at the urotensin receptor (UT) has been shown to improve cardiac function and structural changes of the myocardium in a model of myocardial infarction. " 01/10/2005 - "Vasoconstrictor factors, like urotensin, angiotensin and catecholamines, activate Rho-dependent serine-threonine kinase (Rho-kinase) and inhibition of this pathway represents a novel therapy for cardiovascular diseases with hypertensive syndrome. "
5.	Stroke (Strokes) 09/01/1996 - "Urocortin, a mammalian CRF-related peptide with close sequence homology to fish urotensin, interacts with CRF1, CRF2 receptors and with CRF-BP. These data indicate that CRF receptor antagonists may be useful for the treatment of the disease states where CRF is elevated such as anxiety and depression, anorexia nervosa and stroke and that ligand inhibitors of CRF-BP may be used to elevate brain levels of 'free' urocortin and other CRF-related peptides."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	urotensin II
3.	Urocortins
4.	Proteins (Proteins, Gene)
5.	Ligands
6.	Glucose (Dextrose)
7.	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)
8.	Oxidants (Oxidizing Agents)
9.	Antioxidants
10.	Vasoconstrictor Agents

Related Therapies and Procedures

1.	Therapeutics